How to Structure Repeated IV Ketamine Treatment for Depression
How should clinicians structure and monitor a repeated intravenous ketamine course for depression over the first 6 months of care?
Clinicians often need practical expectations for how frequently to give intravenous ketamine, how long to continue it, and when to judge benefit. This guide summarizes the actual treatment pattern and outcome milestones observed in VA routine care for repeated ketamine infusions.
-
Begin with a higher-frequency acute phase
In the first month after the initial infusion, the mean interval between infusions was 5 days. The study found that more infusions within the first 6 weeks were associated with greater PHQ-9 improvement, with each additional infusion associated with a mean 0.7-point greater improvement in 6-week PHQ-9 score.
-
Expect benefit to accrue over multiple infusions
Do not judge treatment response after only one or two infusions if the patient is continuing treatment. Among patients who ever met improvement criteria, the mean time to minimally clinically important difference was 51 days and 9 infusions, mean time to response was 56 days and 9 infusions, and mean time to remission was 56 days and 10 infusions.
-
Track symptoms with PHQ-9 at infusion visits
This study monitored outcomes using PHQ-9 scores collected at the time of infusion. Use the same thresholds applied in the article to interpret change: minimally clinically important difference as at least a 5-point decrease from baseline, response as a 50% reduction, and remission as a PHQ-9 score of 5 or less.
-
Reassess progress at about 6 weeks
Six weeks is a practical early decision point because the authors selected it as the primary endpoint after visual inspection suggested that most symptom improvement occurred within 6 weeks from the first infusion. At 6 weeks, mean PHQ-9 improvement was 4.6 points, with 47% reaching minimally clinically important difference, 26% response, and 15% remission.
-
Taper infusion frequency if treatment is continued
After the initial month, infusion intervals widened in routine care. Mean intervals increased to 12 to 17 days during months 2 to 4 and then to 23 to 28 days during months 5 to 12, reflecting a practice pattern of acute treatment followed by maintenance-style treatment every 3 to 4 weeks.
-
Monitor treatment over months rather than weeks alone
Most patients continued beyond a short induction series, with 96% receiving additional infusions and a mean total of 18 treatments over 12 months. Mean symptom improvement remained relatively stable at 12 weeks and 26 weeks, with PHQ-9 improvement of 4.4 and 4.7 points respectively among those with available follow-up.
-
Recognize that dose may increase over the course
In this study, mean ketamine dose was 45 mg at the first infusion, 59 mg across all infusions, and 66 mg at the last infusion. These data describe real-world practice patterns rather than an evidence-based titration rule, but they show that dose escalation during ongoing treatment was common.
Clinical Considerations
- The maintenance pattern described here reflects observational practice in VA care and has not been confirmed as an optimal intravenous ketamine schedule in controlled trials.
- The study did not determine the best dose, dosing frequency, or taper strategy for intravenous ketamine.
- PHQ-9 data were available only on infusion dates, which limits assessment of symptom change between treatments.
- The study did not assess safety outcomes such as cardiac events, interstitial cystitis, or substance use disorders.
Bottom Line
For patients continuing intravenous ketamine, use a higher-frequency first 6 weeks, monitor PHQ-9 change over multiple infusions, and expect maintenance-style spacing to widen to every 3 to 4 weeks if benefit is sustained.
